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Chronic active Epstein-Barr virus infection (CAEBV) is a high-mortality and high-morbidity disease. To clarify
the prognostic factors, a national survey was performed in Japan, and data for 82 patients who met the criteria
for CAEBV were analyzed. Of these 82 patients, 47 were alive and 35 had already died. Multivariate analysis
revealed that thromobocytopenia and age at disease onset were correlated with mortality. The probability of
5-year survival was 0.45 for older patients (onset age, 8 years), 0.94 for younger patients ( ), 0.38 forP ! .001
patients with thrombocytopenia (platelet count ! 4 platelets/mL at diagnosis), and 0.76 for patients12 10
without thrombocytopenia ( ). Furthermore, patients with T cell infection by EBV had shorter survivalPp .01
times than patients with natural killer cell infection (probability of 5-year survival, 0.59 vs. 0.87; ).P ! .009
Patients with CAEBV with late onset of disease, thrombocytopenia, and T cell infection had significantly poorer
outcomes.
Epstein-Barr virus (EBV) is a ubiquitous virus; most
individuals are infected with EBV by early adulthood.
Primary EBV infection is usually asymptomatic but
sometimes progresses to infectious mononucleosis,
which resolves spontaneously after the emergence of
EBV-specific immunity [1, 2]. EBV causes chronic in-
fections in apparently immunocompetent hosts [1, 3].
Chronic active EBV infection (CAEBV) is characterized
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by chronic or recurrent infectious mononucleosis–like
symptoms that persist for a long time and by an unusual
pattern of anti-EBV antibodies [4, 5]. Patients with
CAEBV have high virus loads in their peripheral blood
[6]. CAEBV is a high-mortality, high-morbidity disease
with life-threatening complications [7–11]. Recent
studies have indicated that clonal expansion of EBV-
infected T cells and NK cells plays a central role in the
pathogenesis of CAEBV [6, 12].
Treatment regimens for CAEBV have not yet been
established. Antiviral or immunomodulatory agents,
such as acyclovir, ganciclovir, vidarabine, interferon-a,
and interleukin-2, have been tested with limited success
in patients with CAEBV. Immunochemotherapy that
involves etoposide, steroids, and cyclosporin A has been
proposed for use in patients with advanced CAEBV
[13], although no evidence has been forthcoming on
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Table 1. Presence of Epstein-Barr virus–associated antibodies
at diagnosis of infection.
Antibody
No. of
tested
patients
Patients with positive
results of antibody testing
No. (%)
Median
titer (range)
VCA-IgG 81 81 (100) 1280 (20–20,480)
VCA-IgA 57 35 (61) 40 (10–160)
VCA-IgM 62 11 (18) 10 (10–80)
EA-DR-IgG 70 64 (91) 320 (10–20,480)
EA-DR-IgA 45 22 (49) 20 (10–640)
EA-DR-IgM 16 0 (0) NA
EBNA 75 62 (83) 40 (10–1280)
NOTE. EA-DR, early antigens diffuse restricted; EBNA, Epstein-Barr virus
nuclear antigens; NA, not applicable; VCA, viral capsid antigens.
Table 2. Epstein-Barr virus (EBV) load in peripheral blood.
Specimen, method
Patients with positive
results of testing for EBV
No. Median result (range)
Mononuclear cells
In situ hybridization,a % 22 3.1 (0.1–90)
Quantitative PCR,b copies/mg 32 104.3 (101.9–107.0)
White blood cells
Quantitative PCR,b copies/mg 3 105.2 (103.2–105.4)
Plasma or serum
Quantitative PCR,b copies/mL 29 103.8 (102.0–105.7)
a In situ hybridization was performed with the EBV-encoded small RNA 1
probe.
b Quantitative polymerase chain reaction (PCR) was real-time PCR or com-
petitive PCR.
the efficacy of such treatments. Recently, successful treatment
of CAEBV by allogeneic bone marrow transplantation was re-
ported [14–17]. However, hematopoietic stem cell transplan-
tation constitutes a substantial risk to recipient patients. There-
fore, transplantation is indicated only for patients with a poor
prognosis.
The purpose of this study was to clarify the prognosis and
prognostic factors for CAEBV, to facilitate better treatment
choices. We performed a national survey of CAEBV in Japan
and found 82 patients who met the criteria for CAEBV. Clinical
and laboratory data were analyzed and compared between living
and deceased patients with CAEBV. By using multivariate re-
gression analysis, we showed that age at disease onset and throm-
bocytopenia were associated with prognosis. Furthermore, we
demonstrated that patients with T cell infection by EBV had
shorter survival times than those with NK cell infection.
PATIENTS AND METHODS
Data collection. In January 2001, a questionnaire that was
developed by the Japanese Association for Research on Epstein-
Barr Virus and Related Diseases was sent to a total of 953
departments of hematology, pediatrics, dermatology, and oto-
rhinolaryngology, to assess the number of patients with sus-
pected CAEBV in Japan. These departments were chosen to
encompass the majority of the tertiary medical facilities where
patients with CAEBV undergo treatment. Respondents were
asked to include both living and deceased patients who had
been diagnosed with CAEBV after 1990. A total of 164 patients
were reported in returns of the primary questionnaires. Sub-
sequently, a second questionnaire that dealt with matched pa-
tients and sought detailed clinical and laboratory data was sent
to each department. The second questionnaire requested data
on family and medical histories, age at disease onset, signs,
symptoms, complications, laboratory data at diagnosis, EBV-
specific antibodies, virus load, EBV-infected cells, clonality of
EBV, human immunodeficiency virus (HIV) serostatus, surface
marker analysis on peripheral blood cells, cytogenetic study,
lymphocyte mitogen response, HLA, applied therapies, and out-
comes. EBV-infected cells were identified by use of either quan-
titative polymerase chain reaction (PCR) or in situ hybridi-
zation using fractionated cells [18]. The fractionation was
performed either by use of electric or magnetic cell sorting [6].
The clonality of EBV was determined by means of Southern
blotting, using a terminal-repeat probe [19]. A total of 118
patients (an effective response rate of 72%) deemed appropriate
for further study were reported.
Case definition. CAEBV was defined according to the fol-
lowing criteria, which were modified slightly from those de-
scribed elsewhere [5, 6, 10]: (1) illness 3 months duration
(EBV-related illness or symptoms including fever, persistent
hepatitis, extensive lymphadenopathy, hepatosplenomegaly,
pancytopenia, uveitis, interstitial pneumonia, hydroa vaccini-
forme, and hypersensitivity to mosquito bites); (2) increased
amounts of EBV or grossly abnormal levels of EBV antibodies.
Patient positive for 1 factor in each category to be diagnosed
with CAEBV: detection of EBV DNA in tissues or peripheral
blood by Southern blot hybridization; EBV-encoded small RNA
1–positive cells in affected tissues or peripheral blood; 1102.5
copies/mg EBV DNA in peripheral blood mononuclear cells
[18]; and grossly abnormal levels of EBV antibodies [anti–viral
capsid antigen (VCA) IgG titers 5120 or anti–early antigen
(EA) IgG titers 640 [5]; and (3) No evidence of previous
immunological abnormalities or other recent infection that
might explain the observed condition.
All of the questionnaires were thoroughly reviewed by mem-
bers of the Japanese Association for Research on Epstein-Barr
Virus and Related Diseases. Patients in whom the presence of
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Table 3. Comparison of laboratory data at diagnosis of
chronic active Epstein-Barr virus infection between living and
deceased patients.
Laboratory data at diagnosisa
Living
patients
(np 47)
Deceased
patients
(np 35) P
WBC count, cells/mL 6030  4760 4010  2880 .01
RBC count, cells 104/mL 442  56 394  74 .002
Platelet count, platelets 104/mL 22.1  11.1 15.9  8.6 .004
Aspartate aminotransferase, U/L 143  163 146  169 .94
Alanine aminotransferase, U/L 158  210 131 143 .54
Lactate dehydrogenase, U/L 815  1130 900  868 .94
Ferritin, ng/mL 1340  4640 2260  8040 .62
IgG, mg/dL 1870  1010 1920  1190 .85
IgE, IU/mL 3620  6380 437  822 .03
VCA IgG, GMT 1170 1160 .97
EA-DR IgG, GMT 200 370 .25
EBNA, GMT 30 30 .97
NOTE. Data are , unless otherwise indicated. Student’s tmeanSD
test was used to compare laboratory data. Nos. in boldface type indicate
statistically significant results. EA-DR, early antigens diffuse restricted;
EBNA, Epstein-Barr virus nuclear antigens; GMT, geometric mean titer; RBC,
red blood cell; VCA, viral capsid antigen; WBC, white blood cell.
a Time between onset and diagnosis ranged from 3 to 113 months (me-
dian, 12 months).
Table 4. Univariate analysis of factors related with chronic
active Epstein-Barr virus (EBV) infection–associated mortality.
Factor Odds ratio (95% CI) P
Liver dysfunctiona 6.0 (1.80–20.4) .004
Thrombocytopeniab 5.5 (2.12–14.5) .0005
Fever 11 day/week 5.0 (1.62–15.8) .005
Splenomegaly 4.8 (1.46–15.9) .01
Hepatomegaly 3.0 (0.87–10.1) .08
Anemiac 2.5 (1.01–6.17) .047
Age at disease onset 1.07 (1.01–1.13) .01
Infection of T cells 2.5 (0.90–6.9) .08
Lymphadenopathy 1.4 (0.48–2.8) .74
Monoclonality of EBV 0.70 (0.19–2.6) .58
Infection of NK cells 0.36 (0.13–1.01) .05
Hypersensitivity to
mosquito bites 0.24 (0.09–0.71) .006
NOTE. P values were obtained by use of either Fisher’s exact test or x2
test. Nos. in boldface type indicate statistically significant results. Laboratory
data were determined at the time of diagnosis. CI, confidence interval.
a Defined as level of serum alanine aminotransferase 150 U/L.
b Defined as platelet count ! 4 platelets/mL.1510
c Defined as red blood cell count ! 4 cells/mL.40010
CAEBV could not be determined (36 patients) were excluded
from further analysis, and a total of 82 patients were enrolled
in this study.
Statistical analysis. Statistical analysis was conducted by
using StatView software (vers. 5.0; SAS Institute). A 2-tailed
Student’s t test was used to compare the mean values of clinical
and laboratory data for each group. For univariate analysis,
Fisher’s exact or a x2 test was used to compare categorical
variables. Logistic regression analysis was used for multivariate
analysis. The probability of survival was estimated by the Kap-
lan-Meier method. Data for patients with hematopoietic stem
cell transplantation were censored at the time of transplanta-
tion. Differences between the 2 groups were subjected to a log-
rank test. was considered to be statistically significant.P ! .05
RESULTS
Epidemiology. In total, 82 patients with CAEBV (42 male and
40 female patients) were enrolled in this study. The age at the
onset of disease ranged from 9 months to 53 years (mean, 11.3
years). Of the 82 patients, 47 were still alive after 8 months to
18 years of observation (mean, 6.4 years). Thirty-five patients
(43%) had died, after survival periods that ranged from 5 months
to 12 years after onset of CAEBV (mean, 4.3 years). Causes of
death included transplantation-related complications ( ),np 7
malignant lymphoma ( ), digestive tract bleeding/perfora-np 6
tion ( ), hepatic failure ( ), hemophagocytic syndromenp 6 np 3
( ), leukemia ( ), multiple organ failure ( ), un-np 3 np 2 np 2
known ( ), and other ( ). Sixteen patients had un-np 2 np 4
dergone hematopoietic stem cell transplantation. Eight of the 16
were alive after 4–41 months of remission. One patient relapsed
and died shortly afterward. The other 7 patients died of trans-
plantation-related complications, which were defined as com-
plications that occurred within 60 days of transplantation and
were considered to be associated with transplantation and
not with the disease itself. The transplantation-related compli-
cations included sepsis ( ), veno-occlusive disease ( ),np 2 np 1
graft-versus-host disease ( ), thrombotic microangiopathynp 1
( ), pneumonia ( ), and pulmonary edema ( ).np 1 np 1 np 1
There were no remarkable or common family or medical histories
among the patients with CAEBV.
Clinical and laboratory features. The major signs and
symptoms of patients with CAEBV were as follows: fever (92.7%),
hepatomegaly (79.3%), splenomegaly (73.2%), liver dysfunction
(67.1%), thrombocytopenia (45.1%), anemia (43.9%), lymph-
adenopathy (40.2%), hypersensitivity to mosquito bites (32.9%),
skin rash (25.6%), hydroa vacciniforme (9.8%), diarrhea (6.1%),
and uveitis (4.9%). At the time of onset, 42% of the patients
had an infectious mononucleosis–like illness. Life-threatening
complications included hemophagocytic syndrome (24.4%), ma-
lignant lymphoma (18.3%), disseminated intravascular coagu-
lopathy (15.9%), hepatic failure (14.6%), digestive tract ulcer/
perforation (11.0%), coronary artery aneurysms (8.5%), central
nervous system involvement (8.5%), myocarditis (6.1%), inter-
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Table 5. Multivariate analysis of factors related with Epstein-
Barr virus infection–associated mortality.
Factor Odds ratio (95% CI) P
Liver dysfunction 5.2 (0.78–34.8) .07
Thrombocytopenia 7.9 (1.15–54.6) .02
Fever 11 day/week 2.5 (0.52–12.2) .25
Splenomegaly 5.5 (0.73–42.0) .07
Anemia 2.7 (0.38–18.6) .30
Age at disease onset 1.08 (1.01–1.15) .02
NOTE. P values were obtained by use of logistic regression analysis.
Statistically significant results are shown in boldface type. CI, confidence
interval.
Figure. 1. Probability of survival calculated from Kaplan-Meier estimates. A, All patients ( ); probabilities of survival at 5 and 10 years werenp 82
and , respectively. B, Comparison between patients at 8 years from disease onset ( ) and patients at !8 years from0.68 0.06 0.58 0.07 np 45
disease onset ( ); probability of survival at 5 years was for older patients and for younger patients ( ). C,np 37 0.45 0.09 0.94 0.04 P ! .001
Comparison between patients with thrombocytopenia (platelet count ! 4 platelets/mL at diagnosis; ) and those without thrombocytopenia12 10 np 59
(platelet count  4 platelets/mL; ): probability of survival at 5 years was for patients with thrombocytopenia and12 10 np 20 0.38 0.13
for those without thrombocytopenia ( ). D, Comparison between patients with T cell–type disease ( ) and patients with0.76 0.06 Pp .001 np 38
NK cell–type disease ( ); probability of survival at 5 years was for those with T cell–type disease and for those withnp 27 0.59 0.09 0.87 0.07
NK cell–type disease ( ).Pp .009
stitial pneumonia (4.8%), and leukemia (4.8%). With the ex-
ception of the patients who had undergone transplantation, only
4 patients experience remission 3–9 years after onset. The re-
maining patients with CAEBV generally had continuous symp-
toms during the observation periods, although they showed some
fluctuations.
EBV-related antibody titers were measured in 81 patients.
The positivity rates and titers of the antibodies are shown in
table 1. All the patients examined were HIV-antibody negative.
Surface marker analysis was performed in 74 patients: 3 patients
had high CD4 cell counts (defined as 170% of the lympho-
cytes); 5 patients had high CD8 cell counts (defined as 150%
of the lymphocytes); and 15 patients had high CD56 cell
counts (defined as 150% of the lymphocytes). Lymphocyte mi-
togen responses were measured in 34 patients, 32 (94%) of
whom had responses within the normal range. Virus load was
measured in 60 patients by means of quantitative PCR or in
situ hybridization. The data on virus loads in peripheral blood
are summarized in table 2. All the patients examined had high
virus loads and fulfilled 1 criterion, as described in the case
definition. However, virus load values were variable and dif-
ficult to compare, because different analytic methods were used
with different sample sources. The clonality of EBV was ana-
lyzed in 54 patients, of whom 41 (76%) were monoclonal, 7
(13%) were oligoclonal, and 6 (11%) were polyclonal. EBV-
infected cells were as follows: T cells ( patients), NKnp 38
cells ( ), B cells ( ), combined T and NK cellsnp 27 np 2
( ), unclassified ( ), and not done ( ). Althoughnp 3 np 4 np 8
some patients exhibited mixed lineages, in general patients
could be divided into 2 groups: patients with T cell infection
(T cell type; ) and those with NK cell infection (NK cellnp 38
type; ). The 2 patients with B cell infection had thenp 27
typical symptoms and progression of CAEBV and fulfilled the
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disease criteria. In these patients, infection of B cells was con-
firmed by use of a combination of in situ hybridization and
immunohistological analysis of biopsy tissue specimens (cer-
vical lymph node and liver), although infections of T and NK
cells were not completely excluded by this method.
Mortality risk factors. The 82 patients were divided into
living ( ) and deceased ( ) patients, and the clinicalnp 47 np 35
and laboratory characteristics of these groups were compared.
The comparisons of laboratory data at diagnosis are shown in
table 3. The deceased patients had lower white blood cell, red
blood cell, and platelet counts. The living patients had higher
IgE concentrations than did the deceased patients. There were
no differences in the titers of serum transaminases, lactate de-
hydrogenase, and EBV-related antibodies between the 2 groups
at the time of diagnosis.
We also evaluated mortality-associated factors by using uni-
variate and multivariate analyses. First, life-threatening com-
plications were investigated. Although almost all the compli-
cations were significantly related to increased risk of mortality
by univariate analysis, multivariate analysis indicated that di-
gestive tract ulcer/perforation (odds ratio [OR], 11.3; 95% con-
fidence interval [CI], 1.06–120; ) and cardiac compli-Pp .02
cations (coronary artery aneurysms or myocarditis; OR, 7.7;
95% CI, 1.25–47.1; ) were associated with death. How-Pp .02
ever, we considered that these complications were inappropriate
as prognostic factors, because they develop late in disease. In
fact, digestive tract ulceration/perforation is one of the most
frequent causes of death among patients with CAEBV. The
pathogenesis of digestive tract ulcer/perforation is unclear and
may be heterogeneous. In 1 patient with jejunal ulcer and per-
foration, pathological findings showed that EBV-infected T cells
had infiltrated the lamina propria of the mucosa, which in-
dicates the direct invasion of EBV-infected cells.
Then we evaluated factors that were present at the time of
diagnosis or that did not change afterward, which included
major signs and symptoms, laboratory data at diagnosis, age
at disease onset, EBV-specific antibodies, EBV-infected cells,
clonality of EBV, and HLA type. Univariate analysis showed
that liver dysfunction, thrombocytopenia, fever, splenomegaly,
anemia, and disease onset age correlated significantly with in-
creased risk of mortality (table 4). Patients with infections of
the T cells tended to have poorer prognoses. On the other hand,
patients who had infection of the NK cells and hypersensitivity
to mosquito bites generally had better outcomes. Interestingly,
the monoclonality of EBV did not correlate with an increased
risk of mortality. The 6 factors that were associated with mor-
tality by univariate analysis were analyzed further by multi-
variate logistic regression analysis. By using multivariate anal-
ysis, we found that only thromobocytopenia and age at disease
onset were associated with increased mortality (table 5).
Survival probability. The survival probabilities for 82 pa-
tients with CAEBV are shown in figure 1A. The survival rates
were compared between patients who either had or lacked the
risk factors that were identified in the multivariate analysis. In
the comparison of ages at disease onset, “8 years” was chosen
as the cutoff between the younger and older groups, because
the most prominent differences in the 5-year survival rates
occurred at this level. Similarly, 4 platelets/mL was cho-12 10
sen as the cutoff for comparisons of platelet counts. Patients
with late onset (onset age 8 years) had significantly reduced
survival times (figure 1B). The probability of 5-year survival
was for older patients and for younger0.45 0.09 0.94 0.04
patients. Patients with thrombocytopenia (platelet counts
! 4 platelets/mL) also had significantly lower survival12 10
times (figure 1C). We recently reported the results of a small-
scale study in which patients with T cell–type CAEBV had lower
survival times, compared with those with NK cell–type CAEBV
[6]. To confirm this result, the survival probabilities were com-
pared between patients with T cell–type and NK cell–type
CAEBV (figure 1D). Once again, the survival of patients with
T cell–type CAEBV was significantly lower, compared with that
of patients with NK cell–type CAEBV.
DISCUSSION
This is the second national survey of CAEBV to have been
conducted in Japan. The first survey, which was performed in
1989 and reported by Ishihara et al. [20], consisted only of
cases of CAEBV that occurred in children. That survey de-
scribed the clinical and laboratory features of CAEBV and
showed that the disease had high mortality and high morbidity
with life-threatening complications. The present (second) sur-
vey comprised cases of CAEBV infection that had been diag-
nosed after 1990 and included cases of CAEBV in both children
and adults. The clinical features of CAEBV have changed in
the decade that has elapsed between these 2 surveys, which is
probably a result of an increase in the sensitivity of detection.
Indeed, the prevalence of major signs and symptoms in this
survey differs somewhat from the first survey. Recently, cases
of CAEBV have been reported that lacked major organ in-
volvement and in which only skin symptoms, such as hyper-
sensitivity to mosquito bites or hydroa vacciniforme-like erup-
tions, were seen [21–23]. It seems that recent developments in
detecting viral genomes and quantifying virus load have ex-
tended our understanding of the disease.
The pathogenesis of CAEBV is unclear. However, there is
accumulating evidence that clonal expansion of EBV-infected
T or NK cells may be associated with the development of
CAEBV [8, 9, 19, 24–26]. We recently showed that the majority
of patients with CAEBV had either the T or the NK cell type
and that these 2 types have different clinical and laboratory
features [6]. T cell–type disease was characterized by fever and
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high titers of EBV-related antibodies, whereas hypersensitivity
to mosquito bites and high concentrations of IgE were observed
in patients with NK cell–type disease [6]. High concentrations
of IgE and high prevalence of hypersensitivity to mosquito bites
were seen in the living patients in this study, which apparently
reflects the more favorable prognosis of NK cell–type patients.
It remains unclear whether these 2 manifestations of disease
represent different entities or simply appear to be different due
to the nature of the infected cells [6]. Nevertheless, the expan-
sion of EBV-infected T or NK cells may be crucial to the path-
ogenesis of CAEBV [12], because the vast majority of patients
with CAEBV belong to either the T or NK cell–type category.
Interestingly, many papers concerning CAEBV have originated
in Japan. The genetic backgrounds of Japanese people may be
associated with the functions of virus-specific or nonspecific lym-
phocytes that allow for the expansion of EBV-infected T or NK
cells. It is noteworthy that EBV-associated hemophagocytic syn-
drome, in which EBV infection of T cells plays a pivotal role
[27–29], has been reported frequently in East Asia [1]. On the
other hand, CAEBV in the Western hemisphere may not always
be associated with the expansion of EBV-infected T or NK cells.
CAEBV in the Western hemisphere is usually milder than CAEBV
in Japan [30]. CAEBV in Japan may be a different entity from
CAEBV in the West; if so, it would be better to call the Japanese
disease “severe chronic active EBV infection” [10] or “EBV-as-
sociated T/NK cell lymphoproliferative disease” [12].
The types of treatment given could have some effect on the
outcome of CAEBV disease. However, numerous treatments
were administered to each patient in the present study; these
regimens were not standardized, because this study was carried
out at multiple centers and in a retrospective manner. There-
fore, we could not analyze the types of treatment used on the
patients in this study. For CAEBV patient mortality, we iden-
tified several risk factors that were determined at the time of
diagnosis or that did not change afterward. This information
is particularly important in selecting specific treatments. He-
matopoietic stem cell transplantation, which is reported to be
effective in treating CAEBV, constitutes a substantial risk to the
patient. Indeed, 7 of the 16 patients who had undergone trans-
plantation died of transplantation-related complications. Pa-
tients with CAEBV may have a higher risk of transplantation-
related complications, because they often suffer from multiple
organ failure and life-threatening complications [6, 20]. As for
transplantation-related complications, veno-occlusive disease is
of great concern, because most patients with CAEBV have
chronic hepatitis, as shown in this study. Nevertheless, patients
with poor prognoses require aggressive therapies to reduce or
eliminate EBV-infected T or NK cells. Hematopoietic stem cell
transplantation has become substantially safer in recent years.
Furthermore, the outcome of transplantation might improve
if the procedure was implemented before the condition of the
patient deteriorated. From our data, we propose that aggressive
treatments, such as hematopoietic stem cell transplantation,
should be considered for patients who have the following: age
at disease onset8 years, T cell infection, or thrombocytopenia
(platelet count ! 4 platelets/mL). Furthermore, digestive12 10
tract ulcer/perforation and cardiac complications are mortality
risk factors, although by the time these complications become
apparent, it might be too late to formulate treatment strategies.
To confirm the efficacy of transplantation and to establish safer
conditioning regimens, prospective studies are needed in which
larger populations of patients with CAEBV are assessed.
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